CRISPR Therapeutics AG (CRSP)
53.39
+2.95
(+5.85%)
USD |
NASDAQ |
Oct 09, 16:00
53.37
-0.02
(-0.04%)
After-Hours: 20:00
CRISPR Therapeutics Free Cash Flow : -371.32M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -371.32M |
| March 31, 2026 | -401.18M |
| December 31, 2025 | -345.93M |
| September 30, 2025 | -303.14M |
| June 30, 2025 | -325.57M |
| March 31, 2025 | -307.86M |
| December 31, 2024 | -144.68M |
| September 30, 2024 | -191.20M |
| June 30, 2024 | -126.04M |
| March 31, 2024 | -166.55M |
| December 31, 2023 | -269.84M |
| September 30, 2023 | -292.55M |
| June 30, 2023 | -361.81M |
| March 31, 2023 | -376.60M |
| December 31, 2022 | -532.93M |
| September 30, 2022 | -508.63M |
| June 30, 2022 | -515.77M |
| March 31, 2022 | 414.36M |
| December 31, 2021 | 457.27M |
| September 30, 2021 | 465.04M |
| Date | Value |
|---|---|
| June 30, 2021 | 502.19M |
| March 31, 2021 | -309.24M |
| December 31, 2020 | -256.72M |
| September 30, 2020 | -166.85M |
| June 30, 2020 | 45.33M |
| March 31, 2020 | 39.66M |
| December 31, 2019 | 49.99M |
| September 30, 2019 | 18.20M |
| June 30, 2019 | -133.42M |
| March 31, 2019 | -120.60M |
| December 31, 2018 | -99.01M |
| September 30, 2018 | -84.69M |
| June 30, 2018 | -82.89M |
| March 31, 2018 | -74.45M |
| December 31, 2017 | -77.91M |
| September 30, 2017 | -84.96M |
| June 30, 2017 | -77.43M |
| March 31, 2017 | -74.78M |
| December 31, 2016 | -58.33M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Vertex Pharmaceuticals, Inc. | 3.796B |
| Basilea Pharmaceutica AG | 71.34M |
| Santhera Pharmaceuticals Holding AG | -0.8494M |
| BeOne Medicines Ltd. | 1.333B |
| AC Immune SA | -- |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -83.50M |
| Cash from Investing (Quarterly) | -55.66M |
| Cash from Financing (Quarterly) | 7.18M |
| Free Cash Flow Per Share (Quarterly) | -0.8719 |
| Free Cash Flow to Equity (Quarterly) | -80.25M |
| Free Cash Flow to Firm (Quarterly) | -84.15M |
| Free Cash Flow Yield | -7.34% |